BidaskClub upgraded shares of Alder BioPharmaceuticals (NASDAQ:ALDR) from a sell rating to a hold rating in a report published on Thursday.
ALDR has been the topic of a number of other reports. Mizuho assumed coverage on shares of Alder BioPharmaceuticals in a report on Wednesday, September 6th. They issued a buy rating and a $32.00 price target on the stock. Canaccord Genuity assumed coverage on shares of Alder BioPharmaceuticals in a report on Thursday, October 26th. They issued a buy rating and a $20.00 price target on the stock. Royal Bank of Canada started coverage on shares of Alder BioPharmaceuticals in a report on Thursday, September 14th. They issued an outperform rating and a $17.00 price target on the stock. ValuEngine downgraded shares of Alder BioPharmaceuticals from a sell rating to a strong sell rating in a report on Wednesday, October 18th. Finally, BMO Capital Markets restated a buy rating and issued a $22.00 target price on shares of Alder BioPharmaceuticals in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $27.71.
Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) traded up $0.50 during midday trading on Thursday, reaching $13.40. 1,000,100 shares of the company’s stock were exchanged, compared to its average volume of 1,203,733. The company has a market cap of $929.37, a P/E ratio of -2.50 and a beta of 2.48. Alder BioPharmaceuticals has a one year low of $8.60 and a one year high of $25.45.
In other news, insider Mark James Litton sold 16,519 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $10.80, for a total value of $178,405.20. Following the sale, the insider now directly owns 116,451 shares in the company, valued at approximately $1,257,670.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 10.60% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new position in shares of Alder BioPharmaceuticals during the 1st quarter worth about $564,000. Russell Investments Group Ltd. boosted its stake in shares of Alder BioPharmaceuticals by 7.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 42,416 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 2,837 shares during the period. Rhumbline Advisers boosted its stake in shares of Alder BioPharmaceuticals by 8.5% during the 2nd quarter. Rhumbline Advisers now owns 61,416 shares of the biopharmaceutical company’s stock worth $703,000 after purchasing an additional 4,825 shares during the period. State of Wisconsin Investment Board purchased a new position in shares of Alder BioPharmaceuticals during the 2nd quarter worth about $401,000. Finally, SG Americas Securities LLC boosted its stake in shares of Alder BioPharmaceuticals by 109.4% during the 2nd quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 8,140 shares during the period. Hedge funds and other institutional investors own 96.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3127542/alder-biopharmaceuticals-aldr-upgraded-to-hold-at-bidaskclub.html.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.